L
Lillian Werner
Researcher at Harvard University
Publications - 144
Citations - 5672
Lillian Werner is an academic researcher from Harvard University. The author has contributed to research in topics: Prostate cancer & Chronic lymphocytic leukemia. The author has an hindex of 30, co-authored 143 publications receiving 4972 citations. Previous affiliations of Lillian Werner include Beth Israel Deaconess Medical Center & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia
Lili Wang,Michael S. Lawrence,Youzhong Wan,Petar Stojanov,Carrie Sougnez,Kristen E. Stevenson,Lillian Werner,Andrey Sivachenko,David S. DeLuca,Li Zhang,Wandi Zhang,Alexander R. Vartanov,Stacey M. Fernandes,Natalie R. Goldstein,Eric G. Folco,Kristian Cibulskis,Bethany Tesar,Quinlan L. Sievers,Erica Shefler,Stacey Gabriel,Nir Hacohen,Robin Reed,Matthew Meyerson,Todd R. Golub,Eric S. Lander,Donna Neuberg,Jennifer R. Brown,Gad Getz,Catherine J. Wu +28 more
TL;DR: This study defines the landscape of somatic mutations in chronic lymphocytic leukemia and highlights pre-mRNA splicing as a critical cellular process contributing to chronic lymphocrytic leukemia.
SF3B1 and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia
Lili Wang,Michael S. Lawrence,Youzhong Wan,Petar Stojanov,Carrie Sougnez,Kristen E. Stevenson,Lillian Werner,Andrey Sivachenko,David S. DeLuca,Li Zhang,Wandi Zhang,Alexander R. Vartanov,Stacey M. Fernandes,Natalie R. Goldstein,Eric G. Folco,Kristian Cibulskis,Bethany Tesar,Quinlan L. Sievers,Erica Shefler,Stacey Gabriel,Nir Hacohen,Robin Reed,Matthew Meyerson,Todd R. Golub,Eric S. Lander,Donna Neuberg,Jennifer R. Brown,Gad Getz,Catherine J. Wu +28 more
TL;DR: In this article, the authors proposed a method to detect the presence of cancer in the human genome using the Human Genome Research Institute (HGRI) grant U54HG003067.
Journal ArticleDOI
Association of PD-L1 Expression on Tumor Infiltrating Mononuclear Cells and Overall Survival in Patients with Urothelial Carcinoma
Joaquim Bellmunt,Stephanie A. Mullane,Lillian Werner,André P. Fay,Marcella Callea,Jeffrey J. Leow,Mary-Ellen Taplin,Toni K. Choueiri,F.S. Hodi,Gordon J. Freeman,Sabina Signoretti,Sabina Signoretti +11 more
TL;DR: Positive PD-L1 expression in TIMCs was significantly associated with longer survival in those patients who developed metastases and was not predictive of OS, but widely expressed in tumor cell membrane and TIMCs in UC.
Journal ArticleDOI
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition
Jan A. Burger,Dan A. Landau,Amaro Taylor-Weiner,Ivana Bozic,Huidan Zhang,Huidan Zhang,Huidan Zhang,Kristopher A. Sarosiek,Lili Wang,Chip Stewart,Jean Fan,Julia Hoellenriegel,Mariela Sivina,Adrian M. Dubuc,Cameron Fraser,Yu Long Han,Shuqiang Li,Kenneth J. Livak,Lihua Zou,Youzhong Wan,Sergej Konoplev,Carrie Sougnez,Jennifer R. Brown,Lynne V. Abruzzo,Scott L. Carter,Michael J. Keating,Matthew S. Davids,William G. Wierda,Kristian Cibulskis,Thorsten Zenz,Lillian Werner,Paola Dal Cin,Peter Kharchencko,Donna Neuberg,Hagop M. Kantarjian,Eric S. Lander,Stacey Gabriel,Susan O'Brien,Anthony Letai,David A. Weitz,Martin A. Nowak,Gad Getz,Catherine J. Wu,Catherine J. Wu,Catherine J. Wu +44 more
TL;DR: It is demonstrated that the ibrutinib therapy favours selection and expansion of rare subclones already present before ibrUTinib treatment, and insight is provided into the heterogeneity of genetic changes associated with ibrutsinib resistance.
Journal ArticleDOI
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
Susanne H.C. Baumeister,Joana M. Murad,Lillian Werner,Heather Daley,Helene Trebeden-Negre,Joanina K. Gicobi,Adam Schmucker,Jake Reder,Charles L Sentman,David E. Gilham,Frederic Lehmann,Ilene Galinsky,Heidi Dipietro,Kristen Cummings,Nikhil C. Munshi,Richard Stone,Donna Neuberg,Robert J. Soiffer,Glenn Dranoff,Jerome Ritz,Sarah Nikiforow +20 more
TL;DR: Manufactured NKG2D-CAR T cells exhibited functional activity against autologous tumor cells in vitro, but modifications to enhance CAR T-cell expansion and target density may be needed to boost clinical activity.